Vertex Pharmaceuticals Inc

VRTX: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|zbLOCK|FjJ?LOCK|k&Xq$c

Vertex Earnings: Stock Falls After Setback With Pain Treatment Candidate VX-993

In the second quarter, Vertex reported a 12% revenue increase year over year and reiterated its 2025 financial guidance. Management announced its next-generation pain treatment, VX-993, would not advance after it failed to meet its primary endpoint, and shares declined 17% in early trading.

Sponsor Center